All drugs significantly reduced NOX4 expression in IPF patients (Figure 4A), but did not significantly affect NRF2, HO-1, γGCS, SOD1, SOD2, CAT, GLRX, TRX1 and TRX2 expression (Figure 4B–J). This evidence concerns the gene GLRX and idiopathic pulmonary fibrosis.